DNMT1 and Alzheimer disease: This DNMT inhibitor is currently under clinical trials in phases II and III to test the effects of this compound on the prevention of Aβ aggregation to toxic oligomers in AD through the direct binding to the unfolded peptide (ClinicalTrials.gov Identifier: NCT00951834) [145] (Table 1).